Seres Therapeutics Inc
MCRB14.760USD
-0.220-1.47%
Market hours （ET）Quotes delayed by 15 min
129.37MMarket Cap
45.65P/E TTM
More Details of Seres Therapeutics Inc Company
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Seres Therapeutics Inc Info
Ticker SymbolMCRB
Company nameSeres Therapeutics Inc
IPO dateJun 26, 2015
CEOThorell (Marella)
Number of employees103
Security typeOrdinary Share
Fiscal year-endJun 26
Address101 Cambridge Park Drive
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02140
Phone16179459626
Websitehttps://www.serestherapeutics.com/
Ticker SymbolMCRB
IPO dateJun 26, 2015
CEOThorell (Marella)
Company Executives of Seres Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas J. DesRosier, J.D.
Mr. Thomas J. DesRosier, J.D.
Co-President, Co-Chief Executive Officer, Chief Legal Officer, Secretary
Co-President, Co-Chief Executive Officer, Chief Legal Officer, Secretary
7.62K
+2.25%
Dr. Matthew R. Henn, Ph.D.
Dr. Matthew R. Henn, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
7.53K
+65.47%
Mr. Richard N. Kender
Mr. Richard N. Kender
Independent Director
Independent Director
3.17K
--
Dr. Teresa L. Young, Ph.D.
Dr. Teresa L. Young, Ph.D.
Executive Vice President, Chief Commercial and Strategy Officer
Executive Vice President, Chief Commercial and Strategy Officer
--
--
Mr. Paul R. Biondi
Mr. Paul R. Biondi
Independent Director
Independent Director
--
--
Mr. Stephen A. Berenson
Mr. Stephen A. Berenson
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
--
--
Dr. Claire M. Fraser, Ph.D.
Dr. Claire M. Fraser, Ph.D.
Independent Director
Independent Director
--
--
Dr. Hans-Juergen Woerle, M.D., Ph.D.
Dr. Hans-Juergen Woerle, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Marella Thorell
Ms. Marella Thorell
Co-President, Co-Chief Executive Officer, Chief Financial Officer
Co-President, Co-Chief Executive Officer, Chief Financial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas J. DesRosier, J.D.
Mr. Thomas J. DesRosier, J.D.
Co-President, Co-Chief Executive Officer, Chief Legal Officer, Secretary
Co-President, Co-Chief Executive Officer, Chief Legal Officer, Secretary
7.62K
+2.25%
Dr. Matthew R. Henn, Ph.D.
Dr. Matthew R. Henn, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
7.53K
+65.47%
Mr. Richard N. Kender
Mr. Richard N. Kender
Independent Director
Independent Director
3.17K
--
Dr. Teresa L. Young, Ph.D.
Dr. Teresa L. Young, Ph.D.
Executive Vice President, Chief Commercial and Strategy Officer
Executive Vice President, Chief Commercial and Strategy Officer
--
--
Mr. Paul R. Biondi
Mr. Paul R. Biondi
Independent Director
Independent Director
--
--
Mr. Stephen A. Berenson
Mr. Stephen A. Berenson
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Revenue Breakdown
FY2023
FY2022
FY2021
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
126.33M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Flagship Ventures
12.78%
Nestle SA
12.04%
The Vanguard Group, Inc.
3.45%
Marshall Wace LLP
1.39%
BlackRock Institutional Trust Company, N.A.
1.11%
Other
69.24%
Shareholders
Shareholders
Proportion
Flagship Ventures
12.78%
Nestle SA
12.04%
The Vanguard Group, Inc.
3.45%
Marshall Wace LLP
1.39%
BlackRock Institutional Trust Company, N.A.
1.11%
Other
69.24%
Shareholder Types
Shareholders
Proportion
Venture Capital
12.78%
Corporation
12.04%
Investment Advisor
5.29%
Investment Advisor/Hedge Fund
2.87%
Research Firm
1.38%
Hedge Fund
1.26%
Individual Investor
0.53%
Other
63.85%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
253
2.32M
25.69%
-2.26M
2025Q2
284
4.24M
48.50%
-1.01M
2025Q1
303
4.22M
48.29%
-1.11M
2024Q4
311
85.93M
50.33%
-20.68M
2024Q3
330
86.09M
50.57%
-26.54M
2024Q2
336
69.70M
45.95%
-51.91M
2024Q1
345
94.53M
65.81%
-35.72M
2023Q4
345
98.23M
75.49%
-30.72M
2023Q3
356
117.05M
93.47%
-19.47M
2023Q2
384
121.97M
97.71%
-18.66M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Flagship Ventures
1.16M
13.2%
-2.00
-0.00%
Jun 30, 2025
Nestle SA
1.09M
12.44%
+709.39K
+186.83%
Sep 30, 2024
The Vanguard Group, Inc.
292.10K
3.34%
-12.50K
-4.11%
Jun 30, 2025
Marshall Wace LLP
91.41K
1.04%
+91.41K
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
97.67K
1.12%
+13.57K
+16.13%
Jun 30, 2025
Bank Vontobel AG
80.33K
0.92%
+26.03K
+47.93%
Jun 30, 2025
Geode Capital Management, L.L.C.
91.60K
1.05%
+10.66K
+13.17%
Jun 30, 2025
Charles Schwab Investment Management, Inc.
34.88K
0.4%
-6.83K
-16.37%
Jun 30, 2025
State Street Investment Management (US)
26.83K
0.31%
+1.79K
+7.17%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Proshares Ultra Russell 2000
0%
ProShares Hedge Replication ETF
0%
Schwab U.S. Small-Cap ETF
0%
Avantis US Small Cap Equity ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 3000 ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 Covered Call ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Schwab U.S. Small-Cap ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
iShares Russell 3000 ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Apr 14, 2025
Merger
20→1
Date
Type
Ratio
Apr 14, 2025
Merger
20→1
FAQs
Who are the top five shareholders of Seres Therapeutics Inc?
The top five shareholders of Seres Therapeutics Inc are:
Flagship Ventures holds 1.16M shares, accounting for 13.20% of the total shares.
Nestle SA holds 1.09M shares, accounting for 12.44% of the total shares.
The Vanguard Group, Inc. holds 292.10K shares, accounting for 3.34% of the total shares.
Marshall Wace LLP holds 91.41K shares, accounting for 1.04% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 97.67K shares, accounting for 1.12% of the total shares.
Flagship Ventures holds 1.16M shares, accounting for 13.20% of the total shares.
Nestle SA holds 1.09M shares, accounting for 12.44% of the total shares.
The Vanguard Group, Inc. holds 292.10K shares, accounting for 3.34% of the total shares.
Marshall Wace LLP holds 91.41K shares, accounting for 1.04% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 97.67K shares, accounting for 1.12% of the total shares.
What are the top three shareholder types of Seres Therapeutics Inc?
The top three shareholder types of Seres Therapeutics Inc are:
Flagship Ventures
Nestle SA
The Vanguard Group, Inc.
Flagship Ventures
Nestle SA
The Vanguard Group, Inc.
How many institutions hold shares of Seres Therapeutics Inc (MCRB)?
As of 2025Q3, 253 institutions hold shares of Seres Therapeutics Inc, with a combined market value of approximately 2.32M, accounting for 25.69% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -22.81%.
What is the biggest source of revenue for Seres Therapeutics Inc?
In FY2023, the -- business generated the highest revenue for Seres Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
